Uchiyama Nahoko, Kikura-Hanajiri Ruri, Kawahara Nobuo, Haishima Yuji, Goda Yukihiro
National Institute of Health Sciences, Tokyo, Japan.
Chem Pharm Bull (Tokyo). 2009 Apr;57(4):439-41. doi: 10.1248/cpb.57.439.
A new type of designer drug, a cannabinoid analog (1), was found in a herbal product distributed on the illegal drug market in Japan in expectation of its narcotic effect. The structure of 1 was identified by LC-MS, GC-MS, high-resolution MS, and NMR analyses. Compound 1 showed a molecular weight of 332, and accurate mass measurement exhibited its elemental composition to be C(22)H(36)O(2). Together, the mass and NMR spectrometric data revealed that 1 was (1RS,3SR)-3-[4-(1,1-dimethyloctyl)-2-hydroxyphenyl]cyclohexan-1-ol, which was first synthesized in 1979 by a group at Pfizer Inc. and reported as a potent cannabinoid analog possessing cannabinoid receptor binding activity and analgesic activity in the 1990 s. This is the first report to identify a cannabinoid analog in an illegal drug.
在日本非法毒品市场上销售的一种草药产品中发现了一种新型的设计药物——大麻素类似物(1),人们期望它具有麻醉作用。通过液相色谱-质谱联用(LC-MS)、气相色谱-质谱联用(GC-MS)、高分辨率质谱(HR-MS)和核磁共振(NMR)分析确定了1的结构。化合物1的分子量为332,精确质量测定显示其元素组成为C₂₂H₃₆O₂。综合质谱和核磁共振光谱数据表明,1是(1RS,3SR)-3-[4-(1,1-二甲基辛基)-2-羟基苯基]环己醇,该化合物于1979年由辉瑞公司的一个团队首次合成,并在20世纪90年代被报道为一种具有大麻素受体结合活性和镇痛活性的强效大麻素类似物。这是首次在非法药物中鉴定出大麻素类似物的报告。